دورية أكاديمية
Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1
العنوان: | Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1 |
---|---|
المؤلفون: | Uğur Yayla, Mehmet Orkun Sevik, Veysel Levent Karabaş, Özlem Şahin, Abdullah Özkaya, Nursal Melda Yenerel, Banu Açıkalın Öncel, Fatih Bilgehan Kaplan, Ecem Önder Tokuç, Hatice Selen Kanar, Işıl Kutlutürk Karagöz, Ece Başaran Emengen, Ayşe Demirciler Sönmez, Aslan Aykut, Utku Limon, Erdinç Bozkurt, Işılay Özsoy Saygın, Tuğba Aydoğan Gezginaslan, Özlem Aydın Öncü, Esra Türkseven Kumral, Nimet Yeşim Erçalık, Erkan Çelik |
المصدر: | Türk Oftalmoloji Dergisi, Vol 53, Iss 6, Pp 356-368 (2023) |
بيانات النشر: | Galenos Yayinevi, 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Medicine LCC:Ophthalmology |
مصطلحات موضوعية: | anti-vegf, diabetic macular edema, intravitreal injection, real-life study, routine clinical practice, Medicine, Ophthalmology, RE1-994 |
الوصف: | Objectives: This study aimed to report the demographic and clinical characteristics of diabetic macular edema (DME) patients treated with intravitreal injection (IVI) of anti-vascular endothelial growth factors (anti-VEGF) and provide an overview of outcomes during routine clinical practice in Türkiye. Materials and Methods: This retrospective, real-world study included 1,372 eyes (854 patients) treated with a pro re nata protocol by 21 ophthalmologists from 8 tertiary clinics on the Asian side of the Marmara region of Türkiye (MARMASIA Study Group). Five cohort groups were established by collecting the patients’ baseline and 3, 6, 12, 24, and 36-month follow-up data, where each subsequent cohort may include the previous. Changes in best-corrected visual acuity (BCVA, approximate ETDRS letters) and central macular thickness (CMT, μm), number of visits and IVI, and rates of anti-VEGF switch and intravitreal dexamethasone implant (IDI) combination were evaluated. Results: The 3, 6, 12, 24, and 36-month cohorts included 1372 (854), 1352 (838), 1185 (722), 972 (581), and 623 (361) eyes (patients), respectively. The mean baseline BCVA and CMT were 51.4±21.4 letters and 482.6±180.3 μm. The mean changes from baseline in BCVA were +7.6, +9.1, +8.0, +8.6, and +8.4 letters, and in CMT were -115.4, -140.0, -147.9, -167.3, and -215.4 μm at the 3, 6, 12, 24, and 36-month visits (p |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English Turkish |
تدمد: | 1300-0659 2147-2661 |
Relation: | http://www.oftalmoloji.org/archives/archive-detail/article-preview/real-world-outcomes-of-ntravitreal-anti-vascular-e/63937; https://doaj.org/toc/1300-0659; https://doaj.org/toc/2147-2661 |
DOI: | 10.4274/tjo.galenos.2023.56249 |
URL الوصول: | https://doaj.org/article/366bac1877524f1aba6d51d5c33e7bbc |
رقم الأكسشن: | edsdoj.366bac1877524f1aba6d51d5c33e7bbc |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 13000659 21472661 |
---|---|
DOI: | 10.4274/tjo.galenos.2023.56249 |